Suppr超能文献

新型组胺(H2)拮抗剂中毒剂量对大鼠甲状腺的影响。

Effects of toxic doses of a novel histamine (H2) antagonist on the rat thyroid gland.

作者信息

Brown C G, Harland R F, Major I R, Atterwill C K

机构信息

Smith Kline & French Research Ltd, Welwyn, Herts, England.

出版信息

Food Chem Toxicol. 1987 Oct;25(10):787-94. doi: 10.1016/0278-6915(87)90235-3.

Abstract

The oral administration of high doses of a histamine H2 antagonist SK&F 93479 (up to 1000 mg/kg/day) to male rats for up to 21 days resulted in alterations in thyroid morphology indicative of increased activity of the thyroid gland. Measurement of thyroidal 125I incorporation substantiated these findings. Treatment with SK&F 93479 resulted in a dose-dependent increase in thyroidal iodide incorporation. This was apparent after a single dose of the compound and was reversible after dosing for 7 days. The increased incorporation of 125I into the thyroid gland was apparently dependent on thyroid-stimulating hormone (TSH) since both hypophysectomy and pretreatment with thyroxine (T4) markedly reduced thyroidal 125I uptake. Hypothalamic thyrotropin-releasing hormone (TRH) and pituitary TSH concentrations were not altered by SK&F 93479 treatment, and in TRH challenge experiments circulating TSH concentrations showed no change from control levels. These data suggest that hypothalamic-pituitary sensitivity was unaltered by treatment with SK&F 93479. Pharmacological ablation of thyroidal mast-cell function did not alter the thyroid response to 125I accumulation after SK&F 93479 dosing, indicating that the action of the compound is probably not dependent on changes in thyroid mast-cell histamine. Circulating T4 and TSH levels were altered in SK&F 93479-treated rats. Generally, T4 levels were reduced 6 hr after dosing and TSH levels were elevated 24 hr after dosing. Triiodothyronine (T3) levels were unaffected by SK&F 93479 treatment. The effect of SK&F 93479 treatment on T4 clearance was measured by examining the elimination of radioactivity from the circulation of rats previously injected with 125I-labelled T4. One oral dose of 1000 mg SK&F 93479/kg markedly increased T4 clearance. These results suggest that SK&F 93479 affects thyroid activity indirectly by a primary effect on T4 clearance. Reductions in circulating T4 lead to increased TSH levels and subsequent stimulation of thyroid activity.

摘要

对雄性大鼠连续21天口服大剂量组胺H2拮抗剂SK&F 93479(高达1000毫克/千克/天),导致甲状腺形态改变,表明甲状腺活性增强。甲状腺125I摄取量的测定证实了这些发现。用SK&F 93479治疗导致甲状腺碘摄取量呈剂量依赖性增加。单次给药后即可明显看出,给药7天后可逆转。125I进入甲状腺的摄取量增加显然依赖于促甲状腺激素(TSH),因为垂体切除和用甲状腺素(T4)预处理均显著降低了甲状腺125I摄取。下丘脑促甲状腺激素释放激素(TRH)和垂体TSH浓度未因SK&F 93479治疗而改变,在TRH激发实验中,循环TSH浓度与对照水平无变化。这些数据表明,SK&F 93479治疗未改变下丘脑-垂体敏感性。甲状腺肥大细胞功能的药理学消除并未改变SK&F 93479给药后甲状腺对125I积累的反应,表明该化合物的作用可能不依赖于甲状腺肥大细胞组胺的变化。SK&F 93479治疗的大鼠循环T4和TSH水平发生改变。一般来说,给药后6小时T4水平降低,给药后24小时TSH水平升高。三碘甲状腺原氨酸(T3)水平不受SK&F 93479治疗的影响。通过检查先前注射125I标记T4的大鼠循环中放射性的消除来测量SK&F 93479治疗对T4清除的影响。口服1000毫克SK&F 93479/千克显著增加T4清除。这些结果表明,SK&F 93479通过对T4清除的主要作用间接影响甲状腺活性。循环T4的降低导致TSH水平升高,随后刺激甲状腺活性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验